Revenue → Gross profit: $14.9BPharmaceutical → Revenue: $13.6BMedical devices → Revenue: $7.8BRevenue → Cost of revenue: $6.5BGross profit → SG&A: $5.3BOncology → Pharmaceutical: $4.8BImmunology → Pharmaceutical: $4.2BGross profit → Operating profit: $3.7BGross profit → R&D: $3.5BOperating profit → Net profit: $3.3BGross profit → Other: $2.4BOrthopaedics → Medical devices: $2.3BInterventional → Medical devices: $1.8BNeuroscience → Pharmaceutical: $1.8BSurgery → Medical devices: $1.3BPulmonary → Pharmaceutical: $1.0BOther pharma → Pharmaceutical: $0.8BInfectious diseases → Pharmaceutical: $0.8BOperating profit → Tax: $0.5BVision → Medical devices: $0.3BGross profit → Restructuring: $0.2BInterest income → Gross profit: $0.1BImmunology: $4.2BPharmaceutical: $13.6BInfectious diseases: $0.8BNeuroscience: $1.8BOncology: $4.8BPulmonary: $1.0BOther pharma: $0.8BRevenue: $21.4BMedical devices: $7.8BInterventional: $1.8BOrthopaedics: $2.3BSurgery: $1.3BVision: $0.3BGross profit: $15.1BCost of revenue: $6.5BOperating profit: $3.7BSG&A: $5.3BR&D: $3.5BRestructuring: $0.2BOther: $2.4BTax: $0.5BNet profit: $3.3BInterest income: $0.1Bcreated with SankeyArt.comImmunology$4.2BPharmaceutical$13.6B-74% Y/YInfectious diseases$0.8BNeuroscience$1.8BOncology$4.8BPulmonary$1.0BOther pharma$0.8BRevenue$21.4B-64% Y/YMedical devices$7.8B5% Y/YInterventional$1.8BOrthopaedics$2.3BSurgery$1.3BVision$0.3BGross profit$15.1B-2% Y/YCost of revenue$6.5B-3% Y/YOperating profit$3.7B24% Y/YSG&A$5.3B7% Y/YR&D$3.5B3% Y/YRestructuring$0.2B26% Y/YOther$2.4B-65% Y/YTax$0.5B-85% Y/YNet profit$3.3BInterest income$0.1BJohnson & Johnson Q1 FY24 Income Statement
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q2 Q3